Morgan Stanley keeps an Overweight rating and $60 price target on Cytokinetics with a “positive catalyst” call on the stock ahead of earnings. The firm expects positive Phase 3 data for aficamten by year-end as Bristol Myers’ (BMY) Camzyos drug with the same mechanism of action was approved and is on the market, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CYTK:
- Cytokinetics to Announce Third Quarter Results on November 2, 2023
- Cytokinetics price target raised to $58 from $49 at H.C. Wainwright
- Cytokinetics provide update on cardiac myosin inhibitor programs at Analyst Day
- Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
- Cytokinetics price target raised to $65 from $59 at Cantor Fitzgerald